+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07697456

Advanced Therapies Evaluated for Adults With Moderate to Severe Crohns Disease or Ulcerative Colitis in a Phase 2 Basket Study

Led by AbbVie · Updated on 2026-10-27

2000

Participants Needed

66

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Crohns disease and Ulcerative Colitis are types of inflammatory bowel diseases that cause long-lasting, severe inflammation in the digestive tract. Crohns disease can affect any part of the digestive tract causing symptoms like belly pain, diarrhea, tiredness, and weight loss, while Ulcerative Colitis affects the lining of the rectum and colon causing bleeding, belly pain, and diarrhea. This Phase 2 platform basket study is evaluating the safety and effectiveness of advanced therapies in adults with moderately to severely active Crohns Disease or Ulcerative Colitis. The study includes two substudies focusing on different treatment combinations for participants with Crohns Disease or Ulcerative Colitis. Substudy 1 evaluates the combination of risankizumab and trosunilimab ABBV-466, while Substudy 2 evaluates risankizumab combined with ABBV-701 ABBV-7066. Participants will be randomly assigned first to a substudy and then to a treatment arm within that substudy. Treatments involve induction and maintenance doses of risankizumab, trosunilimab, ABBV-701, or their combinations, given via injection or infusion. Participants will attend regular visits at hospitals or clinics for medical assessments including blood and stool tests, endoscopies, monitoring for side effects, and completing questionnaires and daily diaries. The study measures include the percentage of participants achieving endoscopic remission at Week 28 and the number of participants experiencing adverse events up to 98 weeks. Secondary outcomes include clinical remission and response rates at Weeks 12 and 28. The study will monitor participants for up to 98 weeks from the start of treatment.

CONDITIONS

Brief Title

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here